Compare BDN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDN | CTNM |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.7M | 550.7M |
| IPO Year | 1995 | 2024 |
| Metric | BDN | CTNM |
|---|---|---|
| Price | $3.28 | $17.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.0M | 492.0K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ 9.65 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $484,454,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.47 | $8.60 |
| 52 Week High | $4.63 | $17.35 |
| Indicator | BDN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 62.64 |
| Support Level | $2.90 | $13.65 |
| Resistance Level | $3.31 | N/A |
| Average True Range (ATR) | 0.08 | 0.98 |
| MACD | 0.01 | 0.19 |
| Stochastic Oscillator | 74.24 | 85.85 |
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.